About this trial
This longitudinal, prospective observational study aims to evaluate functional status in critically ill adult patients in the Intensive Care Unit using the Chelsea Critical Care Physical Assessment Tool (CPAx). The primary objective is to analyze CPAx score variation as a potential predictor of clinical outcomes, including mortality and duration of mechanical ventilation. Functional assessments will be performed at intensive care unit (ICU) admission and discharge to monitor changes in physical function and to predict adverse clinical outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Pregnancy
Inability to record the CPAx score within the first 48 hours of ICU admission or on the day of ICU discharge
ICU readmission
Known comorbidities causing generalized weakness, such as neuromuscular or neurological diseases
Trial population
The general ICU admits both surgical patients and clinical patients, including those with acute illnesses or decompensations of chronic diseases. Participants include both male and female patients.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
hospital mortality
Mortality will be collected during the period of hospitalization
Secondary outcomes
mechanical ventilation days
It will be collected from the date of intubation in the intensive care unit until the date of extubation or up to 48 hours off mechanical ventilation in cases of tracheostomized patients and/or until the outcome of death
ICU length of stay
It will be collected from the date of intensive care unit admission until the outcome of discharge from the intensive care unit or death.
length of hospital
It will be collected from the date of intensive care unit admission until the outcome of hospital discharge or death.
Extubation rate
Proportion of patients who were extubated during ICU stay.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Universidade Federal do Rio de Janeiro
Lead sponsor
Hospital Universitario Pedro Ernesto
Collaborator
Instituto Nacional de Infectologia Evandro Chagas
Collaborator